Advertisement

New Injectable Agents for the Treatment of Type 2 Diabetes Part 1 – Injectable Insulins

Published:February 26, 2018DOI:https://doi.org/10.1016/j.amjmed.2018.01.049

      Abstract

      The United States Food and Drug Administration has recently approved several new insulin products and new formulations of existing insulin products. These new products may provide advantages over older products, such as a lower risk of nocturnal hypoglycemia and ease of dosing; however, they are costly. The first of 2 articles in a series, this review will describe the potential advantages and disadvantages of these new insulin products.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Professional Practice Committee of the American Diabetes Association
        Standards of medical care in diabetes-2017.
        Diabetes Care. 2017; 40: S64-S74
        • Eli Lilly and Company
        U.S. Food and Drug Administration Approves Humalog® 200 units/mL Kwikpen®.
        (Available at)
        • Barnosky A.
        • Shah L.
        • Meah F.
        • et al.
        A primer on concentrated insulins: what an internist should know.
        Postgrad Med. 2016; 128: 381-390
        • Eli Lilly and Company
        FDA approves Basaglar, a long-acting insulin treatment.
        (Available at)
        • Rosenstock J.
        • Hollander P.
        • Bhargava A.
        • et al.
        Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insuin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study).
        Diabetes Obes Metab. 2015; 17: 734-741
        • Sanofi
        Sanofi receives approval of once daily basal insulin Toujeo.
        (Available at)
        • Dailey G.
        • Lavernia F.
        A review of the safety and efficacy data for insulin glargine 300 units/mL, a new formulation of insulin glargine.
        Diabetes Obes Metab. 2015; 17: 1107-1114
        • Riddle M.C.
        • Bolli G.B.
        • Zieman M.
        • et al.
        New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized, controlled trial (EDITION 1).
        Diabetes Care. 2014; 37: 2755-2762
        • Yki-Jarvinen H.
        • Bergenstal R.
        • Zieman M.
        • et al.
        New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized, controlled trial (EDITION 2).
        Diabetes Care. 2014; 37: 3235-3243
        • Eli Lilly and Company
        U.S. Food and Drug Administration Approves Humulin® U-500 Kwikpen.
        (Available at)
        • Hood R.C.
        • Arakaki R.F.
        • Wysham C.
        • et al.
        Two treatment approaches for human regular U-500 insulin in patients with type 2 diabetes not achieving adequate glycemic control on high-dose U-100 insulin therapy with or without oral agents: a randomized, titration-to-target clinical trial.
        Endocr Pract. 2015; 21 (Erratum, 2016;22(7):905): 782-793
        • Drugs.com
        Tresiba approval history.
        (Available at)
        https://www.drugs.com/history/tresiba.html
        Date accessed: March 9, 2018
        • Rodbard H.W.
        • Gough S.
        • Lane W.
        • et al.
        Reduced risk of hypoglycemia with insulin degludec versus insulin glargine in patients with type 2 diabetes requiring high doses of basal insulin: a meta-analysis of 5 randomized BEGIN trials.
        Endocr Pract. 2014; 20: 285-292
        • Menghini L.
        • Atkin S.L.
        • Gough S.C.L.
        • et al.
        The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: A 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes (BEGIN FLEX Trial).
        Diabetes Care. 2013; 36: 858-864
        • Atkin S.
        • Javed Z.
        • Fulcher G.
        Insulin degludec and insulin aspart: novel insulins for the management of diabetes mellitus.
        Ther Adv Chronic Dis. 2015; 6: 375-388